Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of acipimox on free fatty acids and urinary albumin/creatinine ratio in patients with abnormal glucose tolerance and hypertriglyceridemia
ChiCTR2000040140Phase 4Not yet recruiting
- Sponsor
- Peking University Shougang Hospital
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of acipimox in diabetic glomerulosclerosis, type 2 diabetes mellitus (T2DM), hypertriglyceridemia and 1 more (2 arms), sponsored by Peking University Shougang Hospital. Primary endpoint: Urinary albumin/creatinine ratio (UACR). Planned start Nov 2020; status: not yet recruiting.
02
Drugs
acipimox
03
Conditions
diabetic glomerulosclerosistype 2 diabetes mellitus (T2DM)hypertriglyceridemiaimpaired glucose tolerance (IGT)
Beyond the preview
Go deeper on ChiCTR2000040140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040140.